Glenmark Pharmaceuticals informs about media release

Glenmark Pharmaceuticals has informed that it has attached media release on 3rd May 2021 titled ‘Glenmark launches Ryaltris®-AZ at an affordable price in India which is self?explanatory.

Read More

Glenmark launches Ryaltris-AZ at affordable price in India

Glenmark Pharmaceuticals has launched of Ryaltris-AZ Nasal Spray for the treatment of moderate to severe allergic rhinitis, in India. Glenmark being one of the leaders in respiratory segment, has been the first to l...

Read More

Glenmark Pharma to launch nasal spray Ryaltris in EU

Glenmark Pharmaceuticals is concluding the final, national phase of its marketing approval application process to launch its nasal spray Ryaltris in 17 countries in the European Union (EU).

Ryal...

Read More

Glenmark Pharm surges as its arm files draft red herring prospectus with SEBI for IPO

Glenmark Pharmaceuticals is currently trading at Rs. 580.95, up by 9.05 points or 1.58% from its previous closing of Rs. 571.90 on the BSE.

The scrip opened at Rs. 572.00 and has to...

Read More

Glenmark Pharmaceuticals’ arm files draft red herring prospectus with SEBI for IPO

Glenmark Life Sciences, a wholly owned subsidiary of Glenmark Pharmaceuticals, has on April 16, 2021, filed a draft red herring prospectus with the Securities and Exchange Board of India for an initial public offer,...

Read More

Glenmark Pharmaceuticals informs about proposed IPO of wholly owned subsidiary

Glenmark Pharmaceuticals has informed that Glenmark Life Sciences, a wholly owned subsidiary of Glenmark Pharmaceuticals has on April 16, 2021 filed a draft red herring prospectus with the Securities and Exchange Bo...

Read More

Glenmark Pharmaceuticals informs about media release

Glenmark Pharmaceuticals has informed that it has attached a media release on 24th March 2021 titled ‘Glenmark Pharmaceuticals receives ANDA approval for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 ...

Read More

Glenmark Pharma trades in green on getting USFDA’s nod for Chlorpromazine Hydrochloride Tablets

Glenmark Pharmaceuticals is currently trading at Rs. 467.95, up by 2.30 points or 0.49% from its previous closing of Rs. 465.65 on the BSE.

The scrip opened at Rs. 466.75 ...

Read More

Glenmark Pharma gets USFDA’s nod for Chlorpromazine Hydrochloride Tablets

Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (USFDA) for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg, the generic...

Read More

Glenmark Pharmaceuticals gets $40 million COVID credit line from IFC

Glenmark Pharmaceuticals has got $40 million COVID credit line from International Finance Corporation (IFC). The loan to Glenmark will help it increase the availability of affordable, quality medicines in the countr...

Read More